Journal list Promote Sponsor
verified SJR 1,477 · Q1 • database Scopus / SJR & Web of Science indexed
Current Osteoporosis Reports
United States · Current Science, Inc.
workspace_premium Q1 — Endocrinology, Diabetes and Metabolism lock_open Open Access

Current Osteoporosis Reports

Current Osteoporosis Reports is a journal indexed in SJR in Endocrinology, Diabetes and Metabolism with an H index of 84. It has a price of 3190 €. It has an SJR impact factor of 1,477 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,477.

ISSN: 1544-1873
Publisher: Current Science, Inc.
Category: Endocrinology, Diabetes and Metabolism
Indexation: verifiedScopus / SJR verifiedWeb of Science
open_in_new Portal NPD menu_book Guidelines NPD
schedule CountryOfPapers database fields
SJR Impact Factor trending_up
1,477 Q1
H-index 84
Acceptance rate pie_chart
28% Selective
Source Acceptance_Rate
Time to publication hourglass_top
NPD
Field NPD
Publication cost (APC) payments
3.190 € Open Access
Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

1,477

H-index

84

Docs (year)

58

Docs 3y

192

Total refs

5774

Cites 3y

1023

Citable 3y

192

Cites/Doc 2y

5.48

Ref/Doc

99.55

Immediate OA

3190 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims
rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.
User
* Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Burden of osteoporosis and fractures in developing countries

View more

Zoledronic acid reduces recurrent clinical fracture in patients with hip fracture

View more

Denosumab: What's New?

View more

Defining Zoledronate's Duration of Action and Optimal Dosing Interval for an Effective Therapy

View more

Defective Skeletal Mineralization in Pediatric CKD

View more

Current Understanding of the Pathophysiology of Osteonecrosis of the Jaw

View more

Current technologies in the evaluation of bone architecture

View more

Current Status of the Female Athlete Triad: Update and Future Directions

View more

Correction to: Stopping Denosumab

View more

Controversies in the Management of Secondary Hyperparathyroidism in Chronic Kidney Disease

View more

Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis

View more

Combination therapy for osteoporosis: Considerations and controversy

View more
SHOW MORE ARTICLES

Cellular Processes by Which Osteoblasts and Osteocytes Control Bone Mineral Deposition and Maturation Revealed by Stage-Specific EphrinB2 Knockdown

View more

Adjuvant Endocrine Therapy and Bone Health in Breast Cancer

View more

Bone quality: A perspective from the food and drug administration

View more

Bone loss in patients with breast or prostate cancer

View more

Bone density, geometry, and fracture in elderly men

View more

Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction

View more

Bisphosphonates for postmenopausal osteoporosis: Determining duration of treatment

View more

Assessment of material, structural, and functional properties of the human skeleton by pQCT systems

View more

Assessing bone mass in children and adolescents

View more

Androgen Deprivation and Bone

View more

Anabolic therapy for osteoporosis: Parathyroid hormone

View more

Anabolic Strategies to Augment Bone Fracture Healing

View more

FAQs